Untargeted LC-HRMS Based-Plasma Metabolomics Reveals 3-O-Methyldopa as a New Biomarker of Poor Prognosis in High-Risk Neuroblastoma

Untargeted LC-HRMS Based-Plasma Metabolomics Reveals 3-O-Methyldopa as a New Biomarker of Poor Prognosis in High-Risk Neuroblastoma

Neuroblastoma (NB) is the most common extracranial malignant tumor in children. Although the survival rate of NB has improved over the years, the outcome of NB still remains poor for over 30% of cases. A more accurate risk stratification remains a key point in the study of NB and the availability of...

Full description

Bibliographic Details
Main Authors: Sebastiano Barco, Chiara Lavarello, Davide Cangelosi, Martina Morini, Alessandra Eva, Luca Oneto, Paolo Uva, Gino Tripodi, Alberto Garaventa, Massimo Conte, Andrea Petretto, Giuliana Cangemi
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Oncology
Subjects:
neuroblastoma
metabolomics
biomarker
high resolution mass spectrometry
catecholamines
3-O-methyldopa
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.845936/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.845936/full

Similar Items